Boston Scientific... Ouch...!

How do I spell pain? B! S! X! Yup, this has got to be one of my all time bad trades. I originally purchased Boston Scientific (Ticker: BSX) in January 2003 based on the expected FDA approval of the drug eluting Taxus stents. Everything went according to plans; the company received FDA approval and rapidly gained market share against Johnson & Johnson. The stock took off, but like Nelly Furtado’s song: All Good Things Come to an End and sure enough BSX stock rise came to an abrupt end. They had to recall their stents due to manufacturing defects and Johnson & Johnson started to regain market share. Now the company is facing problems with the Guidant acquisition. I did one of those very bad things in investing, not cutting one's losses. Sometimes, you need something like this to wake you up. I'm wide awake now...